Topic: adverse drug reactions
Redx was hit hard last year when it was forced to suspend a phase 1/2a trial of its porcupine inhibitor for solid tumors, but it’s now been given the OK to restart testing.
Redx hit pause on a trial of its porcupine inhibitor after the first patient to receive the drug suffered “clinically significant” adverse events.
Seattle Genetics has called a halt to all clinical testing of vadastuximab talirine (SGN-CD33A) after seeing a higher rate of patient deaths with the drug in a phase 3 trial.
Roche has revealed that a patient died in a phase 3 hemophilia trial of bispecific antibody emicizumab.